Lothar Bergmann, Viktor Grünwald, Luise Maute, Marc-Oliver Grimm, Steffen Weikert, Jan Schleicher, Theodor Klotz, Jochen Greiner, Anne Flörcken, Arndt Hartmann, Thomas Gauler
- Background: Non-clear cell renal cell cancers (nccRCC) are rare entities, and the optimal therapy in metastatic disease has still to be defined. Methods: In this small prospectively randomized phase IIa multicenter trial, we investigated temsirolimus (TEM) versus sunitinib (SUN) as first-line therapy in patients with metastatic nccRCC. The patients were randomized 1:1 to either TEM in a dose of 25 mg i.v. once a week or SUN with 50 mg p.o. daily for 4 weeks on and 2 weeks off. Primary endpoint was progression-free survival (PFS). In total, 22 patients were included with predominantly papillary RCC (16/22) followed by chromophobe RCC and others. Results: The male to female ratio was 16:6. The tumor control rate (CR + PR + SD) was 58% for TEM and 90% for SUN-treated patients. There was also a trend for improved PFS with 9.3 versus 13.2 months (HR 1.64; 95% CI 0.65–4.18) in favor of SUN. There was no trend for overall survival. Conclusions: Despite this trial had to be terminated earlier due to low recruitment, the results match the other studies published so far with the mTOR inhibitor everolimus and SUN, which show a trend in favor of SUN for ORR and PFS.
MetadatenVerfasserangaben: | Lothar BergmannORCiDGND, Viktor Grünwald, Luise Maute, Marc-Oliver GrimmORCiDGND, Steffen Weikert, Jan Schleicher, Theodor Klotz, Jochen Greiner, Anne Flörcken, Arndt HartmannORCiDGND, Thomas Gauler |
---|
URN: | urn:nbn:de:hebis:30:3-633329 |
---|
DOI: | https://doi.org/10.1159/000508450 |
---|
ISSN: | 2296-5262 |
---|
Titel des übergeordneten Werkes (Englisch): | Oncology research and treatment |
---|
Verlag: | Karger |
---|
Verlagsort: | Basel |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 15.06.2020 |
---|
Datum der Erstveröffentlichung: | 15.06.2020 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 20.10.2021 |
---|
Freies Schlagwort / Tag: | Non-clear cell renal cell cancer; Phase II trial; Randomized trial; Sunitinib; Temsirolimus |
---|
Jahrgang: | 43 |
---|
Ausgabe / Heft: | 7-8 |
---|
Seitenzahl: | 6 |
---|
Erste Seite: | 333 |
---|
Letzte Seite: | 338 |
---|
Bemerkung: | This study was supported by a grant from Pfizer Germany. |
---|
Bemerkung: | Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. |
---|
HeBIS-PPN: | 488130859 |
---|
Institute: | Medizin / Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Lizenz (Deutsch): | Deutsches Urheberrecht |
---|